Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Invetx Inc. currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These filings are distributed across 2 distinct examiners, which suggests a varied approach to the company's current prosecution. This distribution allows the company to test different claim strategies simultaneously and ensures that its progress is not overly dependent on the views of a specific official. Such a strategy can lead to a more robust patent portfolio by incorporating feedback from multiple examiners with different technical perspectives on the company's biological innovations.
The portfolio is active in distinct art units, reflecting a variety of technical focuses within the company's biotechnology innovations. DAHLE, CHUN WU, is the busiest examiner, currently handling 1 pending office action. The company's progress in this sector will depend on successfully addressing the concerns of the assigned examiners. Practitioners should carefully coordinate the responses across these different matters to maintain consistency in the company's technical disclosures and to ensure that all legal positions are aligned across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | — |
| 18396160 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18427351 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §102§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18396160 | POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE | BENAVIDES, JENNIFER ANN | 1675 | §103DP | Non-Final OA | — | Pending | Dec 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInvetx Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Chun Wu Dahle has the most, with 1 of Invetx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
